Product name as reported
Avolve: adverse event reports filed with FDA
533 reports list it as a suspect or interacting product, 2009–2021.
- 533
- reports as suspect product
- 0% of all reports · about 32 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 92.3%
- marked serious by the reporter
- 57.4% across all reports
- 5.1%
- record death among outcomes, as reported
- 27 reports · not verified by FDA
533 adverse event reports received by FDA list the product name "Avolve" as reporters wrote it as a suspect or interacting product, from November 2009 to May 2021. A further 429 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 32 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are urinary retention (8.8%), prostate cancer (6.8%) and dysphagia (3.9%). A report can list several reactions, so shares add to more than 100%; 152 different terms appear across these reports. Urinary retention is recorded in 8.8% of these reports, against 0.2% of all reports in the database.
92.3% of the reports are marked serious by the reporter; 5.1% record death among the outcomes and 27.8% record hospitalisation, as reported. 61.2% of the reports came from consumers, and the largest patient age group is 75 and over (37.1%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
No report listing Avolve was received in the five years to June 2026; the latest was received in May 2021.
By year received
Reactions recorded in the reports
share of Avolve reports recording the termall reports in the database
- Urinary retentionbeing unable to empty the bladder8.8%47
- Prostate cancer6.8%36
- Dysphagiadifficulty swallowing3.9%21
- Alanine aminotransferase increasedraised liver enzyme (ALT)3.2%17
- Aspartate aminotransferase increasedraised liver enzyme (AST)3.2%17
- Hospitalisationadmission to hospital3.2%17
- Wrong technique in product usage processthe product was used in the wrong way3.2%17
- Cerebral infarction2.8%15
- Cardiac failureheart failure2.3%12
- Dysuriapain on passing urine2.1%11
- Product use issuea problem in how the product was used1.9%10
- Condition aggravatedthe condition being treated got worse1.7%9
- Dementiadementia1.3%7
- Interstitial lung diseasescarring or inflammation of lung tissue1.3%7
- Product preparation issuea problem preparing the product1.3%7
- Blood glucose increasedraised blood sugar reading1.1%6
- Anaemialow red blood cells0.9%5
- Decreased appetitereduced appetite0.9%5
- Diabetes mellitusdiabetes0.9%5
- Haematuriablood in the urine0.9%5
- Renal impairmentreduced kidney function0.9%5
- Treatment noncompliancethe treatment was not taken as directed0.9%5
- Arrhythmia0.8%4
- Breast mass0.8%4
Top 30 of 152 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 0.2% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Benign prostatic hyperplasia | 324 | 60.8% |
| Alopecia | 2 | 0.4% |
| Dysuria | 2 | 0.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 533 reports.
In context
| Measure | Avolve | All reports |
|---|---|---|
| Reports as suspect product | 533 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 92.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 51 | 91 |
| Hospitalisation recorded, per 1,000 reports | 278 | 213 |
| Consumer-filed share | 61.2% | 45.8% |
| Top term, share of reports | Urinary retention 8.8% | 0.2% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Avolve reports
How many adverse event reports has FDA received for Avolve?
533 reports list Avolve as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 429 list it only as a concomitant medication.
What reactions are recorded in Avolve reports?
urinary retention (8.8%), prostate cancer (6.8%), dysphagia (3.9%), hepatic function abnormal (3.9%) and alanine aminotransferase increased (3.2%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Avolve was responsible.
How serious are the reports?
92.3% are marked serious by the reporter. Among the outcomes recorded, 5.1% of reports include death and 27.8% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (61.2%), physician (22.5%) and pharmacist (15%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Avolve rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Avolve was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Avolve?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Avolve as a suspect or interacting product; reports listing it only as a concomitant medication (429) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.